Evidence map›Paper›PMID 41301523›Full record

ArticleBiomolecules2025

Nanoparticle-Based Delivery of Resveratrol Suppresses Ehrlich Ascites Carcinoma and Protects Testicular Function via Antioxidant, Anti-Angiogenic, Anti-Inflammatory, and Pro-Apoptotic Mechanisms.

M Alfawaz, Ekramy M Elmorsy, Ahmad Najem Alshammari, Marwa Nagy Emam, Islam Ibrahim Hegab, Aly A M Shaalan, Manal S Fawzy, Lina Abdelhady Mohammed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M AlfawazDepartment of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University, Arar 91431, Saudi Arabia.ORCID 0009-0004-1855-843X
Ekramy M ElmorsyCenter for Health Research, Northern Border University, Arar 73213, Saudi Arabia.ORCID 0000-0002-7444-2499
Ahmad Najem AlshammariDepartment of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University, Arar 91431, Saudi Arabia.ORCID 0009-0003-0057-5672
Marwa Nagy EmamPhysiology Department, Faculty of Medicine, Tanta University, Tanta 31511, Egypt.ORCID 0000-0002-5211-809X
Islam Ibrahim HegabPhysiology Department, Faculty of Medicine, Tanta University, Tanta 31511, Egypt.ORCID 0000-0003-1469-1941
Aly A M ShaalanDepartment of Anatomy, Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0009-0004-5360-5043
Manal S FawzyCenter for Health Research, Northern Border University, Arar 73213, Saudi Arabia.ORCID 0000-0003-1252-8403
Lina Abdelhady MohammedDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Benha University, Benha 13518, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study, for the first time, evaluated the therapeutic potential of resveratrol-loaded phytosome nanoparticles (RES-PNPs) against Ehrlich ascites carcinoma (EAC) and associated testicular dysfunction, compared with free resveratrol (RES). Ninety male Swiss albino mice were divided into six groups, (1) control; (2) RES (10 mg/kg/day, orally); (3) RES-PNPs (10 mg/kg/day, orally); (4) EAC, induced by intraperitoneal injection of 2.5 × 10

Indexed as

Angiogenesis InhibitorsAnti-Inflammatory AgentsAntioxidantsCarcinoma, Ehrlich TumorNanoparticlesResveratrolTestisAnimalsApoptosisMaleMiceAngiogenesis InhibitorsAnti-Inflammatory AgentsAntioxidantsResveratrolanti-angiogenicanti-inflammatoryantioxidantapoptosisEhrlich ascites carcinomaresveratrol-loaded nanoparticlestesticular function

Identifiers

PMID41301523
PMCPMC12650414

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.